Regioselective glucuronidation of tanshinone IIa after quinone reduction: Identification of human UDP-glucuronosyltransferases, species differences, and interaction potential

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1132-1140

  Wang, Qiong ^a   Hao, Haiping ^a   Zhu, Xuanxuan ^b   Yu, Guo ^a   Lai, Li ^a   Liu, Yitong ^a   Wang, Yuxin ^a   Jiang, Shan ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; MYCOPHENOLIC ACID; PROPOFOL; QUINONE DERIVATIVE; TANSHINONE IIA; ABIETANE DERIVATIVE; ISOENZYME; NQO1 PROTEIN, HUMAN; PHENANTHRENE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TANSHINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; ENZYME SUBSTRATE; GLUCURONIDATION; HUMAN; HUMAN CELL; IC 50; INCUBATION TEMPERATURE; ISOMER; LIVER; LIVER CYTOSOL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INTERACTION; RAT; SPECIES DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOMERISM; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT;

CANIS FAMILIARIS; RATTUS;

ANIMALS; DITERPENES, ABIETANE; DOGS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; ISOMERISM; KINETICS; LIVER; MALE; MICE; MICE, INBRED ICR; MYCOPHENOLIC ACID; NAD(P)H DEHYDROGENASE (QUINONE); PHENANTHRENES; PROPOFOL; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 77953845415     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031864     Document Type: Article

References (37)

1. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) The glucuronidation of Delta4 -3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 35:363-370.
3. Dai H, Wang M, Li X, Wang L, Li Y, and Xue M (2008) Structural elucidation of in vitro and in vivo metabolites of cryptotanshinone by HPLC-DAD-ESI-MS(n). J Pharm Biomed Anal 48:885-896.
4. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
5. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, and Kimura I (2008) Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 117:280-295.
6. Hao H, Wang G, Cui N, Li J, Xie L, and Ding Z (2006a) Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med 72:1311-1317.
7. Hao H, Wang G, Cui N, Li J, Xie L, and Ding Z (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8:137-149.
8. Hao H, Wang G, Li P, Li J, and Ding Z (2006b) Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Pharm Biomed Anal 40:382-388. (Pubitemid 43143343)
9. Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, Salonen JS, and Finel M (2008) Regioand stereospecific N-glucuronidation of medetomidine: the differences between UDP gluc- uronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos 36:1529-1537.
10. Kaji H and Kume T (2005a) Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s). Drug Metab Dispos 33:60-67. (Pubitemid 40023515)
11. Kaji H and Kume T (2005b) Regioselective glucuronidation of denopamine: marked species differences and identification of human UDP- glucuronosyltransferase isoform. Drug Metab Dispos 33:403-412.
12. Kim DH, Kim S, Jeon SJ, Son KH, Lee S, Yoon BH, Cheong JH, Ko KH, and Ryu JH (2009) Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal-regulated kinase signalling pathway. Br J Pharmacol 158:1131-1142.
13. Li J, Wang G, Li P, and Hao H (2005) Simultaneous determination of tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography- electrospray ionisation-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 826:26-30. (Pubitemid 41446430)
14. Li P, Wang GJ, Li J, Hao HP, and Zheng CN (2006) Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 41:670-684. (Pubitemid 44023122)
15. Liu J, Wu J, Wang X, and Cai Z (2007) Study of the phase I and phase II metabolism of a mixture containing multiple tanshinones using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:2992-2998.
16. Lu Q, Zhang P, Zhang X, and Chen J (2009) Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med 24:773-780.
17. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
18. Mano Y, Usui T, and Kamimura H (2007) Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos 35:1182-1187. (Pubitemid 46956440)
19. Mano Y, Usui T, and Kamimura H (2008) Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. J Pharm Sci 97:2805-2810.
20. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, and Ritter JK (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520.
21. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, and Redinbo MR (2007) Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369:498-511.
22. Nishiyama T, Ohnuma T, Inoue Y, Kishi T, Ogura K, and Hiratsuka A (2008) UDP-glucuronosyltransferases 1A6 and 1A10 catalyze reduced menadione glucuronidation. Biochem Biophys Res Commun 371:247-250.
23. Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyland quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
24. Ren ZH, Tong YH, Xu W, Ma J, and Chen Y (2010) Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 17:212-218.
25. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, and Marquet P (2010) Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40-45.
26. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
27. Shi SL, Li QF, Liu QR, Xu DH, Tang J, Liang Y, Zhao ZL, and Yang LM (2009) Nuclear matrix protein, prohibitin, was down-regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). J Cell Biochem 108:926-934.
28. Shiratani H, Katoh M, Nakajima M, and Yokoi T (2008) Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
29. Sim SM, Back DJ, and Breckenridge AM (1991) The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol 32:17-21.
30. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
31. Vree TB, Lagerwerf AJ, Bleeker CP, and de Grood PM (1999) Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J Chromatogr B Biomed Sci Appl 721:217-228.
32. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, and WangW(2005) Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116:799-807.
33. Wen Z, Martin DE, Bullock P, Lee KH, and Smith PC (2007) Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos 35:440-448.
34. Wójcikowski J, Pichard-Garcia L, Maurel P, and Daniel WA (2003) Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 138:1465-1474.
35. Zhang Y, Can R, Mao C, Zhang Y, Zhu L, Shao H, Wang L, Wang A, and Xu Z (2009a) The effect of tanshinone IIA on renal and liver functions in ovine fetuses in utero. Drug Chem Toxicol 32:362-371.
36. Zhang Z, Gao J, Wang Y, Song T, Zhang J, Wu G, Zhang T, and Du G (2009b) Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding. Biochem Pharmacol 78:1316-1322.
37. Zhou L, Zuo Z, and Chow MS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345-1359.